Bris­tol My­ers rolls out 3-year mesothe­lioma da­ta for Op­di­vo/Yer­voy in first look at ES­MO slate

The Op­di­vo/Yer­voy im­munother­a­py com­bo from Bris­tol My­ers Squibb has earned some skep­ti­cism over the years from re­searchers ques­tion­ing the ef­fi­ca­cy of CT­LA-4 in fight­ing tu­mors. But in ad­vanced mesothe­lioma, the com­bi­na­tion is show­ing mul­ti-year clin­i­cal ben­e­fit in a par­tic­u­lar­ly dire pa­tient pop­u­la­tion.

Af­ter a min­i­mum of three years fol­low-up, the Op­di­vo-Yer­voy com­bo con­tin­ued to beat out chemother­a­py in terms of ex­tend­ing the lives of pa­tients with un­re­sectable ma­lig­nant mesothe­lioma as a first-line ther­a­py, ac­cord­ing to up­dat­ed da­ta from the CHECK­MATE-743 study set to be pre­sent­ed Fri­day at the ES­MO vir­tu­al con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER